Timothy L Wiemken

Dr. Timothy L Wiemken


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2024 in American Journal of Infection Control
Verified
Journal Article
Closed access
TWTimothy L Wiemken
Timothy L Wiemken
RCRuth M. Carrico
Ruth M. Carrico

1 June 2018 in American Journal of Infection Control
Verified
Journal Article
Closed access
TWTimothy L Wiemken
Timothy L Wiemken
SFStephen P Furmanek
Stephen P Furmanek
WMWilliam A. Mattingly
William A. Mattingly
JHJanet Haas
Janet Haas
JRJulio A Ramirez
Julio A Ramirez
RCRuth M. Carrico
Ruth M. Carrico

20 November 2023 in Microorganisms
Verified
Journal Article
Open access
PDF file
JRJulio A Ramirez
Julio A Ramirez
SFStephen P Furmanek
Stephen P Furmanek
Thomas R ChandlerThomas R Chandler
Thomas R Chandler
TWTimothy L Wiemken
Timothy L Wiemken
PPPaula Peyrani
Paula Peyrani
TGThe University of Louisville Pneumonia Study Group
The University of Louisville Pneumonia Study Group
Streptococcus pneumoniae remains a primary pathogen in hospitalized patients with community-acquired pneumonia (CAP). The objective of this study was to define the epidemiology of pneumococcal pneumonia in Louisville, Kentucky, and to estimate the burden of pneumococcal pneumonia in the United States (US). This study was nested in a prospective population-based cohort study of all adult residents in Louisville, Kentucky, who were hospitalized with CAP from 1 June 2014 to 31 May 2016. In hospitalized patients with CAP, urinary antigen detection of 24 S. pneumoniae serotypes (UAD-24) was performed. The annual population-based pneumococcal pneumonia incidence was calculated. The distribution of S. pneumoniae serotypes was characterized. Ecological associations between pneumococcal pneumonia and income level, race, and age were defined. Mortality was evaluated during hospitalization and at 30 days, 6 months, and 1 year after hospitalization. Among the 5402 CAP patients with a UAD-24 test performed, 708 (13%) patients had pneumococcal pneumonia. The annual cumulative incidence was 93 pneumococcal pneumonia hospitalizations per 100,000 adults (95% CI = 91–95), corresponding to an estimated 226,696 annual pneumococcal pneumonia hospitalizations in the US. The most frequent serotypes were 19A (12%), 3 (11%), and 22F (11%). Clusters of cases were found in areas with low incomes and a higher proportion of Black or African American population. Pneumococcal pneumonia mortality was 3.7% during hospitalization, 8.2% at 30 days, 17.6% at 6 months, and 25.4% at 1 year after hospitalization. The burden of pneumococcal pneumonia in the US remains significant, with an estimate of more than 225,000 adults hospitalized annually, and approximately 1 out of 4 hospitalized adult patients dies within 1 year after hospitalization.